Navigation Links
Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29
Date:7/27/2009

p> 
        Cost of sales increased 3 percent to $527 million in the second
        quarter of 2009 versus $512 million in the second quarter of 2008
        primarily driven by higher fill and finish costs resulting from lower
        utilization at our manufacturing facility in Puerto Rico.

        Research & Development (R&D) expenses were $657 million in the second
        quarter of 2009 versus $779 million in the second quarter of 2008, a
        decrease of 16 percent.  This decrease is in part due to the $100
        million expense in the second quarter of 2008 resulting from the
        upfront payment associated with the Kyowa Hakko collaboration.  The
        remainder of the expense decrease was primarily driven by lower
        clinical trial costs for denosumab and Vectibix registrational
        studies, partially offset by a $50 million expense in the second
        quarter of 2009 resulting from the payment to obtain an exclusive
        license to Cytokinetics' cardiac contractility program.

        Selling, General & Administrative (SG&A) expenses were relatively
        unchanged at $891 million in the second quarter of 2009 versus $894
        million in the prior year.  Lower staff related expenses, lower
        litigation expenses, and lower enterprise resource planning (ERP)
        system related expenses were offset by higher promotional expenses for
        marketed products, increased spending for activities in preparation
        and anticipation of approval and launch of denosumab, and higher
        expenses associated with the Wyeth profit share due to higher ENBREL
        sales.

        Excluding expenses associated with the Wyeth profit share of $301
        million and $283 million in the second quarter of 2009 and 2008,
        respectively, adjusted SG&A expenses in the second quarter of 2009
        decreased 3 percent versus the same quarter last year.


'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related medicine news :

1. Burgeoning Population of Hepatitis C Virus Patients in Need of Second- and Third-Line Treatment Options
2. Medical Services International Maintains Pace in Second Quarter
3. CEOs Need an Advertising Check Up or Second Opinion
4. Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card
5. HealthMedia Revolution Explodes in Second Quarter
6. J.D. Power and Associates Reports: CIGNA HealthCare Recognized for Call Center Customer Satisfaction Excellence For a Second Consecutive Year
7. Acting Surgeon General Announces National Initiatives to Protect Children by Reducing Exposure to Secondhand Smoke
8. Roller Derby Author Cheats Death a Second Time
9. Launch of second European Cancer Research Funding survey
10. Secondhand smoke increases teen test failure
11. Elder Care Author Doctor Marion Launches Second National Tour to Raise Awareness About Aging & Elder Care Issues in America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Stem cells that could one day provide therapeutic ... harvested from the tissue of the umbilical cord, just ... cells to treat some blood disorders, said University of ... version of the Journal of Biomedicine and ... be expanded to greater number, are remarkably stable and ...
(Date:12/17/2009)... Vomiting syndrome made him a recluse at times, ... -- An Australian researcher claims he has identified ... Darwin to suffer nausea, vomiting, headaches and skin ... Numerous mental and physical diagnoses have been suggested ... that Darwin would become a virtual recluse for ...
(Date:12/17/2009)... the aging inequity , , THURSDAY, Dec. 17 ... gender inequity: Women develop more and deeper wrinkles ... do. , The disadvantage had long been suspected, ... said Dr. Foad Nahai, a plastic surgeon practicing ... Surgery Journal . The study appears in the ...
(Date:12/17/2009)... of nimotuzumab , ... (PRWEB) ... Therapure Biopharma Inc. and David Allan, Chairman and CEO of ... under which Therapure Biopharma will provide aseptic fill and finish ... majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of ...
(Date:12/17/2009)... -- Over the last few weeks there has been ... is used by e cigarette opposition in an attempt ... are questioning the tactics of these groups when the ... safer alternative to tobacco according to several studies, lab ... specialist around the world. ,, Special interest groups ...
Breaking Medicine News(10 mins):Health News:Umbilical cord could be new source of plentiful stem cells, say Pitt researchers 2Health News:New Theory Emerges on Darwin's Illness 2Health News:Mouth Area Wrinkles More in Women Than Men 2Health News:Mouth Area Wrinkles More in Women Than Men 3Health News:Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership 2Health News:Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership 3Health News:Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership 4Health News:Special Interest Deceptions Continue to Rampant About Electronic Cigarettes 2
... fertility can feel a bit relaxed now. Genosis Inc, a ... called Fertell. The test has his and hers components ... at-home device to measure the concentration of motile sperm, and ... marker of egg quality. ,The availability of the ...
... can cause disorders in their children, says the BMA. ... which are part of fetal alcohol spectrum disorders ... the individual and those around them. A new BMA ... completely preventable by not drinking any alcohol during pregnancy. ...
... Mental Health Services Administration (SAMHSA) today announced that ... three years to the state of Iowa ... The first year award is $400,000. This grant ... intervention and treatment services for youth suicide prevention ...
... studies have already revealed that stress boosts the production ... a new study on mice has now shown that ... ,The study, reported online in the Proceedings of ... University School of Medicine in St. Louis, is among ...
... NORTH HOLLYWOOD, Calif., and CHICAGO, The International Myeloma ... and support for myeloma patients, families, researchers and ... a Phase 3 multi- national clinical trial shows ... probability of survival by 41%. ,The ...
... out in the morning, before they have eaten anything, a ... at promoting weight loss as it boosts hormones that ... College London conducted the study on 12 volunteers who were ... meal, half of the volunteers were asked to work out ...
Other Medicine News:Health News:Fertility Test at Home Possible With a New Kit 2Health News:Pregnancy and Alcohol - a Dangerous Cocktail Warns BMA Scotland 2Health News:Iowa to Receive Grant Funding for Youth Suicide Prevention, Early Intervention 2Health News:Stress Protein Inactivation Cuts Alzheimer's Peptide in Mice 2Health News:Velcade(R) Plus Doxil(R) Improves Previously Treated Multiple Myeloma Patients 2Health News:Exercise After Meals Helps Better to Lose Pounds 2
(Date:12/16/2009)... -- HDT Engineered Technologies (HDT), a leader in ... principal subcontractor for the mechanical development of the ... anthropromorphic arm technology that will give patients improved, ... including a sense of touch. ,, As ... (DARPA) Revolutionizing Prosthetics 2009 (RP2009) project, the MPL ...
(Date:12/16/2009)... International, Inc. (OTCQX: DATA), a technology and ... for the clinical trials industry, today announced ... Software. This release advances the Company,s ... and introduces two new mechanisms for facilitating ... Center(TM) and the DATATRAK Learning Manager(TM). ...
(Date:12/16/2009)... Iceland, December 16 Scientists at,deCODE genetics, ... Nature the,discovery of a version of a common ... (SNP) with a major impact on susceptibility to ... variant is not only large, but unusual:,if an ... increases risk of,T2D by more than 30% compared ...
Breaking Medicine Technology:HDT Develops Robotic Arm Technology for DARPA's Revolutionizing Prosthetics 2009 Program 2DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 2DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 3DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 4deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4Inherited Risk Factors Increase Odds of Developing Childhood Acute Lymphoblastic Leukemia 54596 1Inherited Risk Factors Increase Odds of Developing Childhood Acute Lymphoblastic Leukemia 54596 2Inherited Risk Factors Increase Odds of Developing Childhood Acute Lymphoblastic Leukemia 54596 3Inherited Risk Factors Increase Odds of Developing Childhood Acute Lymphoblastic Leukemia 54596 4New biomarker predicts response to hepatitis C treatment 54593 1New biomarker predicts response to hepatitis C treatment 54593 2New biomarker predicts response to hepatitis C treatment 54593 3New biomarker predicts response to hepatitis C treatment 54593 4Inherited risk factors increase odds of developing childhood acute lymphoblastic leukemia 9587 1Inherited risk factors increase odds of developing childhood acute lymphoblastic leukemia 9587 2Inherited risk factors increase odds of developing childhood acute lymphoblastic leukemia 9587 3
... Finds Statins Cut Risk of Heart Attacks, Deaths, ... cause of death among Americans, costing our healthcare,system hundreds ... is new hope for preventing this fatal disease - ... A new study has found that millions of ...
... Venter Shares Award with James D. Watson, Marilyn & James ... ROCKVILLE, Md., Nov. 12 J. Craig Venter,Ph.D., Founder and ... Double Helix Medal from Cold Spring Harbor Laboratory (CSHL) on,November ... Dr. Venter received the Double Helix Medal along with Dr. ...
Other Medicine Technology:Seniors Can Be Heartened by New Study on Statins 2J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory 2
... the Anterior Segment The BD is optimized ... ophthalmologists specializing in the anterior segment. It is ... c-mount camera on the BD 900- may be ... in 10 and 16 X times- through the ...
... The BP 900 offers ... Designed for routine practice, the ... optical system and progressive functionality. ... for video, one for digital ...
... The NanoChip 400 System is an automated ... for performing SNP detection, pathogen sequence detection ... targets can be applied to an open ... which may be reused until all tests ...
... for venous pressure monitoring, blood sampling, ... Turbo-Flo polyurethane PICC line sets offer:, ... Micropuncture Introducer Needle, Biocompatible ... trimmed to patient specific anatomy. Remove ...
Medicine Products: